Mignani Renzo, Berti Gian Marco, Vischini Gisella, Di Costanzo Roberta, Ciurli Francesca, Vetrano Daniele, Biagini Elena, Serratore Serena, Fabbrizio Benedetta, Pasquinelli Gianandrea, La Manna Gaetano, Capelli Irene
Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Orphanet J Rare Dis. 2025 Sep 2;20(1):468. doi: 10.1186/s13023-025-03994-9.
RATIONALE & OBJECTIVE: Late-onset Anderson-Fabry disease appears in adulthood, usually with prevalent cardiac involvement. The N215S (p.Asn215Ser) missense mutation represents the most frequent late-onset variant in European countries. The N215S nephropathy was then investigated from a clinical and histopathological point of view.
Renal and cardiac assessments were evaluated at baseline. The standardized scoring system of histologic involvement proposed by International Study Group of Fabry Nephropathy was applied to kidney biopsies, performed before the treatment start. A deeper digital histological reinterpretation was provided in a subgroup. Treated patients' renal function was evaluated at diagnosis (T0), after 5 years (T1) and after 10 years (T2) from the treatment start.
SETTING & PARTICIPANTS: 27 patients (11 males, 16 female) with a N215S variant were evaluated.
Mean eGFR at diagnosis was 84.98 ± 26.4 mL/min/1.73m, and 6 patients were CKD-stage 3-5. In the 24 treated patients, the mean T0 eGFR was 86.5 ± 28.01 mL/min/1.73m; 26% with CKD-stage 3-5 (mean eGFR 45.3 ± 19.4 mL/min/1.73m). At T1, the mean eGFR in 14/24 patients was 69.1 mL/min/1.73m and 35% with CKD-stage 3-5 (mean eGFR 33.3 ± 17.1 mL/min/1.73m). T2 was evaluated in 6 patients, of which 5/6 (85%) with CKD-stage 3 (mean eGFR 43.2 ± 20 mL/min/1.73m). 18/18 patients presented kidney biopsies with different degrees of podocyte vacuolization, while sclerosis was documented in 9/18. 14/18 patients showed a higher podocyte vacuolization score. Males showed significant greater interstitial fibrosis (p 0.016). Arteriolar intimal fibrosis significantly correlated with eGFR at baseline (p 0.09).
The main limitation was the number of patients, as well as the number of available kidney and cardiac biopsies.
Even at early stages, N215S patients display typical histological abnormalities of Fabry disease. Moreover, chronic kidney disease seems to progress over time in treated patients, with arterial and arteriolar intimal fibrosis.
迟发型安德森-法布里病出现在成年期,通常心脏受累较为普遍。N215S(p.Asn215Ser)错义突变是欧洲国家最常见的迟发型变异。随后从临床和组织病理学角度对N215S肾病进行了研究。
在基线时评估肾脏和心脏情况。将法布里肾病国际研究组提出的组织学受累标准化评分系统应用于治疗开始前进行的肾活检。对一个亚组进行了更深入的数字组织学重新解读。在治疗开始后的诊断时(T0)、5年后(T1)和10年后(T2)评估接受治疗患者的肾功能。
对27例携带N215S变异的患者(11例男性,16例女性)进行了评估。
诊断时的平均估算肾小球滤过率(eGFR)为84.98±26.4 mL/min/1.73m²,6例患者为慢性肾脏病3 - 5期。在24例接受治疗的患者中,T0时的平均eGFR为86.5±28.01 mL/min/1.73m²;26%为慢性肾脏病3 - 5期(平均eGFR 45.3±19.4 mL/min/1.73m²)。在T1时,14/24例患者的平均eGFR为69.1 mL/min/1.73m²,35%为慢性肾脏病3 - 5期(平均eGFR 33.3±17.1 mL/min/1.73m²)。对6例患者进行了T2评估,其中5/6(85%)为慢性肾脏病3期(平均eGFR 43.2±20 mL/min/1.73m²)。18/18例患者的肾活检显示足细胞有不同程度的空泡化,9/18例有硬化表现。14/18例患者的足细胞空泡化评分较高。男性的间质纤维化明显更严重(p = 0.016)。小动脉内膜纤维化与基线时的eGFR显著相关(p = 0.09)。
主要局限性在于患者数量以及可用的肾脏和心脏活检数量。
即使在早期阶段,N215S患者也表现出法布里病典型的组织学异常。此外,在接受治疗的患者中,慢性肾脏病似乎随时间进展,伴有动脉和小动脉内膜纤维化。